Clinical trials: Huntington's Dementia
Huntington Disease
Hinting Task for Huntington's Disease
Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder, characterized by movement disorders, behavioural disorders and cognitive decline.
- Trial name
- HT-HD (NCT06774443)
- Testing
- Neuropsychological assessment
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
Huntington Disease
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
- Trial name
- NCT05358717
- Testing
- PTC518
- Where
- 28 sites in United States, Australia and 9 more
- Volunteers
- 159 people
- Sponsor
- Novartis Pharmaceuticals
Huntington's Disease
Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability
The purpose of this clinical trial is to extend the Pre-Crest-X study to further assess the long-term safety and tolerability of up to 30 grams daily creatine in individuals at-risk for Huntington's Disease (HD) and to assess…
- Trial name
- Pre-CREST-2X (NCT01411163)
- Testing
- Creatine monohydrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Huntington's Disease
Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BN82451B versus placebo after oral administration twice daily (bid) for 28 days in patients with Huntington's Disease…
- Trial name
- NCT02231580
- Testing
- BN82451B
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ipsen
Huntington's Disease
A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi
The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.
- Trial name
- SIGNAL-HD (NCT02481674)
- Testing
- VX15/2503
- Where
- 32 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Vaccinex Inc.
Huntington Disease, Chorea
Citalopram to Enhance Cognition in HD
This research plan proposes to conduct a double-blind, placebo-controlled pilot clinical trial in 36 adults with mild Huntington's disease (HD) to address the following research aims: 1.
- Conditions
- Huntington Disease, Chorea, Executive Dysfunction
- Trial name
- CIT-HD (NCT00271596)
- Testing
- 20mg daily citalopram
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Iowa
Huntington Disease
PHysical Activity and Exercise Outcomes in Huntington's Disease
Huntington's disease (HD) is a genetic, degenerative neurological disease that affects individuals in their third-fourth decade of life and individuals can live 15-20 years with manifest HD.
- Trial name
- PACE-HD (NCT03344601)
- Testing
- physical activity
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 116 people
- Sponsor
- Cardiff University
Huntington's Disease
Exercise Effects in Huntington's Disease
Huntington's disease (HD) is an incurable and fatal disorder characterised by progressive degeneration of the basal ganglia and the cerebral cortex.
- Trial name
- NCT01879267
- Testing
- Exercise training
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Huntington Disease, Pain
Huntington's Disease and Pain
The primary objective of this pilot study is to assess the feasibility of three internationally agreed pain test batteries in patients with Huntington Disease.
- Trial name
- HD-P1 (NCT06693466)
- Testing
- Facial expression block, Conditioned pain modulation block, Pain facilitation block
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Leiden University Medical Center
Huntington Disease
Symptomatic Therapy for Patients With Huntington's Disease
Based on the previous symptomatic treatment of Chinese HD patients, this study intends to further optimize the treatment regimen of Chinese HD patients so as to further improve the prognosis of patients.
- Trial name
- NCT04071639
- Testing
- Haloperidol 2Mg Tab, Risperidone 1Mg Tab, Zoloft 50Mg Tablet
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Huntington Disease
IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
iMarkHD is an adaptive, longitudinal positron emission tomography (PET) and magnetic resonance (MR) imaging study in Huntington's disease (HD) that aims to assess abnormal molecular, functional, and structural changes in…
- Trial name
- NCT03434548
- Testing
- PET imaging, Multi-modal MRI imaging
- Where
- United Kingdom
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- King's College London
Brain Neuroimaging Biomarkers in Huntington Disease
Dynamic Neuroimaging Biomarkers in Huntington's Disease
There is no curative treatment available today in Huntington disease (HD) despite the identification of the mutated gene 20 years ago.
- Trial name
- HDeNERGY (NCT02639871)
- Where
- France
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
Trial of the Combined Use of Thiamine and Biotin in Patients With Huntington's Disease
Evaluate the safety and tolerability of combined oral thiamine with biotin therapy in patients with Huntington´s disease in mild to moderate stages and it is intended to evaluate the biological effect of the treatment in the…
- Trial name
- HUNTIAM (NCT04478734)
- Testing
- Moderate doses of Thiamine y Biotin, High doses of Thiamine y Biotin
- Where
- 3 sites in Spain
- Volunteers
- 24 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Huntington Disease
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
- Trial name
- NCT05358821
- Testing
- SAGE-718
- Where
- 14 sites in United States, Canada
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Supernus Pharmaceuticals, Inc.
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Huntington's Disease
Exploring Computerised Cognitive Training for People With Huntington's Disease
Cognitive impairments, especially deficits of executive function, have been well documented as a core and early feature in Huntington's disease (HD).
- Trial name
- CogTrainHD (NCT02990676)
- Testing
- Computerised cognitive training
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cardiff University
Huntington Disease
Pilot Study of Minocycline in Huntington's Disease
This study is being conducted to assess the impact of minocycline on the progression of symptoms of HD. The study will also assess whether it is reasonable to continue with further study of minocycline in HD.
- Trial name
- NCT00277355
- Testing
- minocycline
- Where
- 12 sites in United States, Canada
- Volunteers
- 114 people
- Sponsor
- Merit Cudkowicz
Huntington Disease
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
WVE-HDSNP2-002 is an open-label extension (OLE) study to evaluate the safety, tolerability, PK, PD, and clinical effects of WVE-120102 in adult patients with early manifest HD who carry a targeted single nucleotide polymorphism…
- Trial name
- NCT04617860
- Testing
- WVE-120102
- Where
- 20 sites in Australia, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Wave Life Sciences USA, Inc.
Huntington's Disease
Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
PRECISION-HD2 is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of WVE-120102 in…
- Trial name
- PRECISION-HD2 (NCT03225846)
- Testing
- WVE-120102
- Where
- 26 sites in United States, Australia and 6 more
- Volunteers
- 88 people
- Sponsor
- Wave Life Sciences USA, Inc.